Re: Gold Nanoshell-Localized Photothermal Ablation of Prostate Tumors in a Clinical Pilot Device Study

2020 ◽  
Vol 203 (1) ◽  
pp. 31-31
Author(s):  
Samir S. Taneja
2010 ◽  
Vol 125 (1) ◽  
pp. 27-34 ◽  
Author(s):  
Laura B. Carpin ◽  
Lissett R. Bickford ◽  
Germaine Agollah ◽  
Tse-Kuan Yu ◽  
Rachel Schiff ◽  
...  

2007 ◽  
Vol 177 (4S) ◽  
pp. 52-52
Author(s):  
Joshua M. Stem ◽  
Jer-Tsang Hsieh ◽  
Sangtae Park ◽  
Yair Lotan ◽  
Jeffrey A. Cadeddu

2007 ◽  
Vol 177 (4S) ◽  
pp. 210-211 ◽  
Author(s):  
Joshua M. Stern ◽  
Jennifer Stanfield ◽  
Jer-Tsang Hsieh ◽  
Jeffrey A. Cadeddu

2016 ◽  
Author(s):  
Suzan Stelloo ◽  
Ekaterina Nevedomskaya ◽  
Karianne Schuurman ◽  
Lodewyk FA Wessels ◽  
Rui Henrique ◽  
...  

2020 ◽  
Vol 4 (5) ◽  
pp. 805-812
Author(s):  
Riska Chairunisa ◽  
Adiwijaya ◽  
Widi Astuti

Cancer is one of the deadliest diseases in the world with a mortality rate of 57,3% in 2018 in Asia. Therefore, early diagnosis is needed to avoid an increase in mortality caused by cancer. As machine learning develops, cancer gene data can be processed using microarrays for early detection of cancer outbreaks. But the problem that microarray has is the number of attributes that are so numerous that it is necessary to do dimensional reduction. To overcome these problems, this study used dimensions reduction Discrete Wavelet Transform (DWT) with Classification and Regression Tree (CART) and Random Forest (RF) as classification method. The purpose of using these two classification methods is to find out which classification method produces the best performance when combined with the DWT dimension reduction. This research use five microarray data, namely Colon Tumors, Breast Cancer, Lung Cancer, Prostate Tumors and Ovarian Cancer from Kent-Ridge Biomedical Dataset. The best accuracy obtained in this study for breast cancer data were 76,92% with CART-DWT, Colon Tumors 90,1% with RF-DWT, lung cancer 100% with RF-DWT, prostate tumors 95,49% with RF-DWT, and ovarian cancer 100% with RF-DWT. From these results it can be concluded that RF-DWT is better than CART-DWT.  


2021 ◽  
Vol 14 (2) ◽  
pp. 103
Author(s):  
Zohaib Rana ◽  
Joel D. A. Tyndall ◽  
Muhammad Hanif ◽  
Christian G. Hartinger ◽  
Rhonda J. Rosengren

Androgen receptor (AR)-null prostate tumors have been observed in 11–24% of patients. Histone deacetylases (HDACs) are overexpressed in prostate tumors. Therefore, HDAC inhibitors (Jazz90 and Jazz167) were examined in AR-null prostate cancer cell lines (PC3 and DU145). Both Jazz90 and Jazz167 inhibited the growth of PC3 and DU145 cells. Jazz90 and Jazz167 were more active in PC3 cells and DU145 cells in comparison to normal prostate cells (PNT1A) and showed a 2.45- and 1.30-fold selectivity and higher cytotoxicity toward DU145 cells, respectively. Jazz90 and Jazz167 reduced HDAC activity by ~60% at 50 nM in PC3 lysates. At 4 μM, Jazz90 and Jazz167 increased acetylation in PC3 cells by 6- to 8-fold. Flow cytometry studies on the cell phase distribution demonstrated that Jazz90 causes a G0/G1 arrest in AR-null cells, whereas Jazz167 leads to a G0/G1 arrest in DU145 cells. However, apoptosis only occurred at a maximum of 7% of the total cell population following compound treatments in PC3 and DU145 cells. There was a reduction in cyclin D1 and no significant changes in bcl-2 in DU145 and PC3 cells. Overall, the results showed that Jazz90 and Jazz167 function as cytostatic HDAC inhibitors in AR-null prostate cancer cells.


Sign in / Sign up

Export Citation Format

Share Document